Cartesian Therapeutics, Inc.

NasdaqGM:RNAC Stock Report

Market Cap: US$479.6m

Cartesian Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Cartesian Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-26.6%

Buyback Yield

Total Shareholder Yield-26.6%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Cartesian Therapeutics: Uncertainty Remains

Nov 10

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 17

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 02

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if RNAC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RNAC's dividend payments have been increasing.


Dividend Yield vs Market

Cartesian Therapeutics Dividend Yield vs Market
How does RNAC dividend yield compare to the market?
SegmentDividend Yield
Company (RNAC)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (RNAC) (up to 3 years)n/a

Notable Dividend: Unable to evaluate RNAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RNAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate RNAC's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RNAC has not reported any payouts.


Discover strong dividend paying companies